Ingevity Corporation
NGVT
$71.64
-$0.39-0.54%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.17B | 1.18B | 1.18B | 1.14B | 1.20B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.17B | 1.18B | 1.18B | 1.14B | 1.20B |
| Cost of Revenue | 706.10M | 695.90M | 698.90M | 659.20M | 729.00M |
| Gross Profit | 461.50M | 479.90M | 477.60M | 484.80M | 471.10M |
| SG&A Expenses | 171.20M | 167.80M | 161.60M | 153.60M | 157.70M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | 500.00K |
| Total Operating Expenses | 905.70M | 891.20M | 887.20M | 837.70M | 911.20M |
| Operating Income | 261.90M | 284.60M | 289.30M | 306.30M | 288.90M |
| Income Before Tax | -142.00M | -12.60M | -20.80M | -41.80M | -140.50M |
| Income Tax Expenses | 8.30M | 39.30M | 24.40M | 3.10M | -19.10M |
| Earnings from Continuing Operations | -150.30 | -51.90 | -45.20 | -44.90 | -121.40 |
| Earnings from Discontinued Operations | -3.10M | -300.00K | -157.70M | -157.70M | -157.70M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -167.10M | -65.90M | -216.60M | -353.80M | -430.30M |
| EBIT | 261.90M | 284.60M | 289.30M | 306.30M | 288.90M |
| EBITDA | 361.00M | 381.10M | 386.40M | 407.50M | 397.20M |
| EPS Basic | -4.63 | -1.80 | -5.95 | -9.74 | -11.85 |
| Normalized Basic EPS | 2.93 | 6.07 | 6.08 | 6.78 | 6.03 |
| EPS Diluted | -4.66 | -1.83 | -5.94 | -9.73 | -11.84 |
| Normalized Diluted EPS | 2.91 | 6.05 | 6.08 | 6.77 | 6.02 |
| Average Basic Shares Outstanding | 144.81M | 145.44M | 145.47M | 145.35M | 145.23M |
| Average Diluted Shares Outstanding | 145.74M | 146.36M | 145.90M | 145.78M | 145.38M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |